Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
r-HuEPO for Malignant Spinal Cord Compression
NCT00220675Phase 3Terminated
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Aug 2005
- Primary completion
- Jul 2007
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in malignant spinal cord compression (MSCC) comparing r-HuEPO Arm with Placebo Arm (2 arms). Primary endpoints: Overall survival, Recovery of ambulation and 1 more. Started Aug 2005; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
malignant spinal cord compression (MSCC)
Beyond the preview
Go deeper on NCT00220675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220675.